On average, JQ1 treatment decreases BRD4 binding intensity in DLBCL SEs by 85% in 24 hours, with SS-to-SE converting regions showing the steepest decrease in magnitude (Student’s t-test P < 10−10 versus all SEs, Fig. S16). The gene discussed is BRD4; the disease is diffuse large B-cell lymphoma.